LiDCO's sales to grow 18%

Cardiovascular monitoring company LiDCO expects revenue in the six months ended 31 July to be 18% ahead of the first half of 2010.The firm predicts sales to be at least £3.1m, compared to the £2.66m reported the year before, while losses are said to have been "significantly reduced". Pre-tax losses totalled £0.57m in the six months to 31 July 2010."We are pleased to be reporting another period of strong financial progress for the Company. Furthermore, during the period we have signed three distribution and licensing arrangements with Argon Medical Devices Inc, Argon Medical Devices Japan and ICU Medical Inc., providing access to the largest markets globally," said chief executive officer Terry O'Brien."These collaborations both extend our hemodynamic monitoring product range sold by our own direct sales force to customers in the UK and adds to our growing base of marketing partners."Shares rose 3.64% to 14.25p 13.59.BC